Filters
Other countries
Results: 1 to 20 of 20
| Tests names and labs | Conditions | Genes, analytes, and microbes | Methods |
|---|---|---|---|
Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey | 1 | 1 |
|
Osteofibrous dysplasia, susceptibility to, 607278, Autosomal dominant (MLPA) Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey | 1 | 1 |
|
DNA Labs India India | 1 | 1 |
|
Centogene AG - the Rare Disease Company Germany | 113 | 68 |
|
Centogene AG - the Rare Disease Company Germany | 155 | 107 |
|
Centogene AG - the Rare Disease Company Germany | 218 | 135 |
|
MET - NGS including CNV analysis Centogene AG - the Rare Disease Company Germany | 5 | 1 |
|
Invitae Comprehensive Deafness Panel Labcorp Genetics (formerly Invitae) LabCorp United States | 405 | 219 |
|
Labcorp Genetics (formerly Invitae) LabCorp United States | 409 | 164 |
|
Labcorp Genetics (formerly Invitae) LabCorp United States | 160 | 62 |
|
Hereditary Hearing Loss and Deafness Panel PreventionGenetics, part of Exact Sciences United States | 361 | 224 |
|
Dhiti Omics Technologies Private Ltd India | 135 | 84 |
|
Detection of MET amplification in gastric cancer Genologica Medica Spain | 4 | 1 |
|
Non-syndromic hearing loss panel. 95-gene NGS panel. Genologica Medica Spain | 146 | 94 |
|
Hereditary endocrine cancer panel. NGS panel of 22 genes. Genologica Medica Spain | 68 | 22 |
|
Hereditary kidney cancer panel. NGS panel of 26 genes. Genologica Medica Spain | 74 | 26 |
|
Institute for Human Genetics University Medical Center Freiburg Germany | 4 | 1 |
|
Comprehensive Hereditary Cancer Panel Baylor Genetics United States | 132 | 61 |
|
Baylor Genetics United States | 41 | 13 |
|
Hereditary onco-endocrino tumors (50 genes) Center for Human Genetics Cliniques Universitaires Saint Luc Belgium | 25 | 49 |
|
Results: 1 to 20 of 20
IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.